Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression

  title={Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression},
  author={Jianfeng Wang and Yunze Xu* and Yun Zou and Liangsong Zhu and Baijun Dong and Jiwei Huang and Yonghui Chen and Wei Xue and Yiran Huang and Wen Kong and Jin Zhang},
  journal={Tumor Biology},
Renal cell carcinoma (RCC) is a common urologic tumor with a poor prognosis. Cannabinoid receptor 1 (CB1), which is a G protein-coupled receptor, has recently been reported to participate in the genesis and development of various cancers. However, the exact role of CB1 in RCC is unknown. The aim of this study was to determine the role of CB1 in RCC cell lines and RCC prognosis, thus underlying its potential as a therapeutic target. Immunohistochemistry and western blots were performed to… 
Molecular Mechanism of Cannabinoids in Cancer Progression
The mechanism of action of the cannabinoids in signaling pathways involved in cancer proliferation, neovascularisation, migration, invasion, metastasis, and tumor angiogenesis is explored.
Cannabinoid pharmacology in cancer research: A new hope for cancer patients?
Endocannabinoid System and Tumour Microenvironment: New Intertwined Connections for Anticancer Approaches
Light is shed on the latest relevant findings of the tumour response to ECS modulation, encouraging a more in-depth analysis in this field, and novel discoveries could be promising for novel anti-tumour approaches, targeting the microenvironmental components and the supportive tumour:stroma crosstalk.
Modulation of the Endocannabinoid System as a Potential Anticancer Strategy
This review gives an overview of the modulation of the extended endocannabinoid system using the example of anticancer cannabinoid effects, which have been described in detail in preclinical studies.
Synergistic interaction of the cannabinoid and death receptor systems – a potential target for future cancer therapies?
This review summarizes recent findings on the interaction of the cannabinoid and DR systems and suggests possible clinical co‐application of cannabinoids and DR ligands in the treatment of various malignancies.
Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges
The objective of the current article is to highlight the putative therapeutic potential of targeting cannabinoid signaling, to identify open questions and key challenges, and to suggest promising future directions for cannabinoid-based drug development.


Cannabinoid CB1 Receptor Is Downregulated in Clear Cell Renal Cell Carcinoma
  • G. Larrinaga, Sanz Begoña, I. Jose
  • Biology, Medicine
    The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • 2010
The obtained data suggest a possible implication of the endocannabinoid system in renal carcinogenesis and a posttranscriptional downregulation of CB1 and the absence of expression of CB2 characterize CCRCC.
Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma.
Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms
The endocannabinoid/CB1R system is up‐regulated in chemically induced HCC, resulting in the induction of various tumor‐promoting genes, including indoleamine 2,3‐dioxygenase; and attenuation of these changes by blockade or genetic ablation of CB1R suppresses the growth of HCC and highlights the therapeutic potential of peripheral CB1 R blockade.
A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer.
Expression of cannabinoid receptors type 1 and type 2 in non‐Hodgkin lymphoma: Growth inhibition by receptor activation
The results suggest that therapies using cannabinoid receptor ligands will have efficiency in reducing tumor burden in malignant lymphoma overexpressing CB1 and CB2.
Cannabinoid CB1 receptor is expressed in chromophobe renal cell carcinoma and renal oncocytoma.
Loss of cannabinoid receptor 1 accelerates intestinal tumor growth.
The genetic and pharmacologic studies reveal that loss or inhibition of CB1 accelerated intestinal adenoma growth in Apc(Min/+) mice whereas activation ofCB1 attenuated intestinal tumor growth by inducing cell death via down-regulation of the antiapoptotic factor survivin.
Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells
It is shown that a majority of human brain tumor samples and cell lines over-expressed cannabinoid receptor CB1 as compared to normal human astrocytes, while uniformly expressed low levels of CB2, indicating that CB1 and STAT3 participate in a new oncogenic network in the complex biology of glioma and their expression levels in patients dictate the efficacy of the CB1 antagonist SR141716 in multimodal gliomas destruction.
AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells
This study provides the first evidence of a proapoptotic effect and G2/M cell cycle arrest of AM251 on A375 cells, and this compound may be a potential prototype for the development of promising diarylpyrazole derivatives to be evaluated in human cutaneous melanoma.
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
It is shown that local administration of the selective CB(2) agonist JWH-133 at 50 microg/day to Rag-2(-/-) mice induced a considerable regression of malignant tumors generated by inoculation of C6 glioma cells, and showed that selective activation of the CB( 2) receptor signaled apoptosis via enhanced ceramide synthesis de novo.